- GBI & PARTNERS
- Immunochina to ramp up cell therapy development after finance round
Immunochina to ramp up cell therapy development after finance round
Beijing-based biotech Immunochina Pharmaceuticals reportedly raised RMB 100 million via Series C+ financing round, funneled by Zhongguancun Longmen Investment. Proceeds will go towards research and development (R&D) of the firm's novel cancer therapy pipeline, and to prepare for commercialization. Previously, Immunochina raised RMB 150 million (around USD 22 million) via a Series C financing round held in January 2019.
Founded in 2015, Immunochina applies cutting-edge gene cell therapy technologies to treat malignant tumors. Notably, its chimeric antigen receptor (CAR) T cell product IM19 won an ethical approval from the Beijing Cancer Hospital (BCH) for assessment in recurrent/refractory (r/r) non-Hodgkin’s lymphoma (nHL) in July this year. In addition, the company is developing several CAR-T cell therapies targeting hematological and solid tumors, with investigational new drug (IND) filings expected next year.